Ralmitaront

Ralmitaront
Clinical data
Other names	RG-7906; RG7906; RO-6889450; RO6889450
Identifiers
	IUPAC name 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide;
CAS Number	2133417-13-5;
PubChem CID	130429734;
ChemSpider	88298290;
UNII	QA8MW1Q80P;
KEGG	D11830;
ChEMBL	ChEMBL4594376;
CompTox Dashboard (EPA)	DTXSID901336976 ;
Chemical and physical data
Formula	C17H22N4O2
Molar mass	314.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C;
	InChI InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1; Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N;

Ralmitaront (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which was undergoing a Phase II clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder, but the trial was discontinued due to lack of efficacy.^[1]^[2]^[3]^[4] Another Phase II clinical trial targeting acute psychotic symptoms of schizophrenia was also terminated for the same reason.^[5] It is a partial agonist of the TAAR1 protein.^[6] The medication is being developed by the pharmaceutical company Hoffmann-La Roche.^[1] Ralmitaront had completed Phase I clinical trials.^[1]^[7]

References

^ ^a ^b ^c "Ralmitaront - Roche". AdisInsight. Springer Nature Switzerland AG.
^ Gomes FV, Grace AA (April 2021). "Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention". International Journal of Molecular Sciences. 22 (9): 4467. doi:10.3390/ijms22094467. PMC 8123139. PMID 33922888.
^ Clinical trial number NCT04512066 for "Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of RO6889450 (Ralmitaront) in Patients With Schizophrenia or Schizoaffective Disorder and Negative Symptoms" at ClinicalTrials.gov
^ "Roche Terminates Second Phase II Schizophrenia Trial". BioSpace. 2023-05-23. Retrieved 2025-04-06.
^ Clinical trial number NCT03669640 for "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder" at ClinicalTrials.gov
^ "Ralmitaront: Relationships: Trace Amine-Associated Receptor 1". Global Substance Registration System (GSRS). U.S. Food and Drug Administration.
^ Clinical trial number NCT02699372 for "The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers" at ClinicalTrials.gov

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.